Hemochromatosis - Pipeline Insight, 2022

Hemochromatosis - Pipeline Insight, 2022

DelveInsight’s, “Hemochromatosis – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hemochromatosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Hemochromatosis Understanding

Hemochromatosis: Overview

Hemochromatosis is the abnormal accumulation of iron in parenchymal organs, leading to organ toxicity. It is the most common autosomal recessive genetic disorder and the most common cause of severe iron overload. There are two types of hemochromatosis, each with different causes. An inherited genetic change is the most common cause. It’s called primary hemochromatosis, hereditary hemochromatosis or classical hemochromatosis. With primary hemochromatosis, problems with the DNA come from both parents and cause the body to absorb too much iron. In secondary hemochromatosis, medical treatments or other medical conditions cause the iron overload. Men have hemochromatosis more than women. Women lose iron when they get their periods or have babies. Not every person with hemochromatosis develops symptoms. Some people with high levels of iron don’t have any problems, while others experience very serious symptoms. Symptoms usually don’t appear until middle age, and they often look like signs of other conditions. Diagnosis for hemochromatosis is based on blood tests to check levels of iron and certain proteins in the blood and to check for gene mutations that commonly cause hemochromatosis. Treatment of hemochromatosis is done with phlebotomy, or drawing about a pint of blood at a time, on a regular schedule. Another option is chelation. This is a developing therapy that can help manage iron levels, but it is expensive and not a first-line treatment option.

""Hemochromatosis - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hemochromatosis pipeline landscape is provided which includes the disease overview and Hemochromatosis treatment guidelines. The assessment part of the report embraces, in depth Hemochromatosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hemochromatosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hemochromatosis R&D. The therapies under development are focused on novel approaches to treat/improve Hemochromatosis.

Hemochromatosis Emerging Drugs Chapters

This segment of the Hemochromatosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hemochromatosis Emerging Drugs

PTG-300: Protagonist Therapeutics

PTG-300 is an injectable hepcidin mimetic in clinical development for the potential treatment of beta-thalassemia, polycythemia Vera (PV) and hereditary hemochromatosis (HH). Hepcidin is a natural peptide hormone that regulates iron absorption and utilization in the body through sequestration and release from tissue macrophages and intestinal enterocytes. Iron plays an essential role in various body functions, especially blood formation. PTG-300 can potentially reduce the need for phlebotomies, such as in the treatment of PV and HH, and the need for transfusions and chelation therapies in thalassemia and myelodysplastic syndrome. A Phase II study of a novel hepcidin mimetic PTG-300 in patients with hereditary hemochromatosis has been initiated.

•STP 251G: Sirnaomics

STP251G is in preclinical development for Hemochromatosis and Hypertriglyceridemia, formulated with Sirnaomics' proprietary GalAhead™ platform.

Further product details are provided in the report……..

Hemochromatosis: Therapeutic Assessment

This segment of the report provides insights about the different Hemochromatosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hemochromatosis

There are approx. 5+ key companies which are developing the therapies for Hemochromatosis. The companies which have their Hemochromatosis drug candidates in the most advanced stage, i.e. Phase II include, Protagonist Therapeutics.

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Hemochromatosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hemochromatosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hemochromatosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hemochromatosis drugs.

Hemochromatosis Report Insights

Hemochromatosis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Hemochromatosis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Hemochromatosis drugs?

How many Hemochromatosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hemochromatosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hemochromatosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Hemochromatosis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

•La Jolla Pharmaceutical Company

•Sirnaomics

•Protagonist Therapeutics

Key Products

•LJPC 401

•STP 251G

•PTG-300